Carbonite Announces Pricing of Private Offering of $125

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
46
Carbonite Announces Pricing of Private Offering of $125 Million of 2.50% Convertible Senior Notes

BOSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Carbonite, Inc. (NASDAQ: CARB ) (“Carbonite” or the “Company”) announced today the pricing of its previously announced private offering of $125 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 (the “notes”) in a private offering. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Carbonite also has granted to the initial purchasers of the notes a 30-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes, solely to cover over-allotments. The offering of the notes is expected to close on April 4, 2017, subject to customary closing conditions.

The notes will be Carbonite’s senior unsecured obligations. The notes will bear interest at a rate of 2.50% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning on October 1, 2017. The notes will mature on April 1, 2022, unless earlier repurchased, redeemed or converted.

The initial conversion rate for the notes is 38.7034 shares of Carbonite’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $25.84 per share of Carbonite’s common stock), which represents an approximately 32.50% conversion premium over the last reported sale price of $19.50 per share of Carbonite’s common stock on the Nasdaq Global Market on March 29, 2017.

Prior to January 1, 2022, the notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Carbonite will satisfy any conversion elections by paying or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election.

Carbonite intends to use (i) approximately $40.0 million of the net proceeds from the offering to repay all amounts outstanding under its revolving credit facility, including the related letters of credit, and to terminate the facility (ii) approximately $15.0 million of the net proceeds from the offering to repurchase shares of its common stock from purchasers of notes in the offering in privately negotiated transactions effected through one or more of the initial purchasers or their affiliates conducted currently with the pricing of the notes and (iii) the remaining net proceeds for general corporate purposes, including potential acquisitions.

The purchase price per share of Carbonite’s common stock in repurchases conducted concurrently with the pricing of the notes was equal to the last reported sale price of $19.50 per share of its common stock on the Nasdaq Global Market on March 29, 2017.  Any such repurchases may increase, or prevent a decrease in, the market price of Carbonite’s common stock or the notes, which could result in a higher effective conversion price for the notes.

The notes and shares of Carbonite common stock issuable upon conversion, if any, have not been registered under the Securities Act, or under any U.S. state securities laws or other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Carbonite

Carbonite (NASDAQ: CARB ) is a leading provider of cloud and hybrid data protection solutions for small and midsized businesses. Together with its partners, Carbonite supports more than 1.5 million individuals and small businesses around the world who rely on it to ensure their important data is protected, available and useful.

Cautionary Language Concerning Forward-Looking Statements

Certain matters discussed in this press release have "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements may generally be identified as such because the context of such statements will include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or words of similar import. Similarly, statements that describe the Company's future plans, objectives or goals are also forward-looking statements.  Such statements include, but are not limited to, the expected closing date and the expected use of the net proceeds from the sale of the notes. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including, but not limited to economic conditions and markets (including current financial conditions), exchange rate fluctuations, risks associated with debt prepayment, stock repurchases or acquisitions in lieu of retaining such cash for future needs, and changes in regulatory conditions or other trends affecting the Internet and the information technology industry. These and other important risk factors are discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the Securities and Exchange Commission (the "SEC"), which is available on www.sec.gov, and elsewhere in any subsequent periodic or current reports filed by us with the SEC. Except as required by applicable law, the Company does not undertake any obligation to update its forward-looking statements to reflect future events, new information or circumstances.

Jeremiah Sisitsky investor.relations@carbonite.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Conformal Coatings Market Set for Significant Growth by 2032

Updated Category News Views 233

The conformal coatings market surged ahead with projections showing it could reach USD 1.7 billion by 2032. This translates into a compound annual growth rate (CAGR) of 5.7% from 2024 to 2032, driven primarily by advancements in electronic protection technologies. Traders had better keep their eyes peeled—this ain't just a bump; it's a substantial shift. What’s...

Continue Reading
Japanese Mobile Battery Industry Forecasts Significant Growth

Updated Category News Views 122

Japan Mobile Battery Market Overview The mobile battery market in Japan is witnessing significant growth, with a valuation of JPY 207.96 billion in 2024 and projected to escalate to JPY 358.97 billion by 2033, marking a compound annual growth rate (CAGR) of 6.48% from 2025 to 2033. This growth trajectory highlights not only increasing consumer demands but also rapidly...

Continue Reading
Givastomig: A Promising Player in Gastric Cancer Therapy

Updated Category News Views 74

Givastomig's Advances in Gastric Cancer Research I-Mab (NASDAQ: IMAB), a biotech firm focused on developing cancer immunotherapies, recently presented exciting results from its Phase 1 clinical trial involving givastomig. This innovative bispecific antibody immunostimulant was unveiled at a prominent medical conference, demonstrating its effectiveness in treating advanced...

Continue Reading
Rani Therapeutics Partners with Chugai for Drug Delivery Breakthrough

Updated Category News Views 245

Rani Therapeutics Engages with Chugai Pharmaceutical Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) recently announced a significant collaborative effort with Chugai Pharmaceutical Co., Ltd., resulting in an enthusiastic response from investors. This collaboration aims to utilize Rani's innovative RaniPill oral drug delivery system alongside Chugai's experimental...

Continue Reading
Revizto's Brand Revamp: A Bold Step Towards Future Growth

Updated Category News Views 142

Revizto Introduces a Fresh Brand Identity As project complexities continue to rise in the construction industry, Revizto is making important modifications to its public image. The renowned collaboration platform, specifically designed for the Architecture, Engineering, Construction, and Operations (AECO) sectors, recently unveiled its refreshed brand identity,...

Continue Reading